BMS 188667 [CTLA41g] may be beneficial in the treatment of rheumatoid arthritis

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1363, 2002-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

In patients with rheumatoid arthritis (RA) "cholesterol-reducing therapies may be beneficial"

By  

Inpharma, Vol. 1, Iss. 1603, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

CTLA4-Ig promising in rheumatoid arthritis

By  

Inpharma, Vol. 1, Iss. 1414, 2003-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Sulfasalazine + methotrexate beneficial for rheumatoid arthritis

By  

Inpharma, Vol. 1, Iss. 1577, 2007-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Leflunomide for the treatment of rheumatoid arthritis

By Miceli-Richard Corinne   Dougados Maxime  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 6, 2003-06 ,pp. : 987-997

Informa Healthcare

Access to resources Recommend Favorite

Targeted treatment for rheumatoid arthritis

By  

Inpharma, Vol. 1, Iss. 1424, 2004-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite